Twist offers new gene fragments to the synthetic biology market

By The Science Advisory Board staff writers

December 11, 2020 -- Twist Bioscience has launched its new clonal-ready gene fragments. The gene fragments, with and without adapters, can be used to rapidly build constructs and minimize the time and cost of screening for clones.

Twist's gene fragments begin as oligonucleotides synthesized on the company's semiconductor-based silicon platform. The oligonucleotides are then annealed with polymerase chain reaction (PCR)-amplified to produce double-stranded DNA fragments. The fragments are error-corrected through an enzymatic reaction process. The final products are ready-to-use gene fragments that are compatible with many applications including cloning, gene and protein expression, pathway and enzyme engineering, and enzyme optimization.

Twist Bioscience touts positive preclinical data for SARS-CoV-2 antibodies
Twist Bioscience has touted preclinical results for three of its proprietary antibodies against the novel coronavirus S1 subunit protein.
Firms partner with Microsoft to advance DNA data storage
Twist Bioscience, Illumina, and Western Digital have formed an alliance with Microsoft to advance the field of DNA data storage.
ImmunoPrecise, Twist collaborate on novel therapeutics
ImmunoPrecise subsidiary Talem Therapeutics and Twist Bioscience will collaborate on the creation of novel therapeutic molecules.
Twist Bioscience finds new SARS-CoV-2 neutralizers
Twist Bioscience has identified immunoglobulin G antibodies and single dose domain VHH nanobodies that have neutralizing effects against SARS-CoV-2.
Twist Bioscience, Seismic Bio partner to discover bispecific antibodies
Twist Bioscience and Seismic Bio have formed a partnership to discover and optimize antibodies to high-value immuno-oncology targets.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter